2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective.
Charles P HannonSusan M GoodmanMatthew S AustinAdolph YatesGordon GuyattVinay K AggarwalJoshua F BakerPhyllis BassDelamo Isaac BekeleDanielle DassHassan M K GhomrawiDavid S JevsevarChian K KwohClaudette M LajamCharis F MengLarry W MorelandLinda I SuleimanJesse WolfstadtKimberly BartosiakNicholas A BedardJason L BlevinsAnna Cohen-RosenblumP Maxwell CourtneyRuth Fernandez-RuizElizabeth B GausdenNilasha GhoshLauren K KingAlexa Simon MearaBella MehtaReza MirzaAdam J RanaNancy SullivanMarat TurgunbaevKatherine D WyshamKevin YipLinda YueMichael G ZywielLinda RussellAmy S TurnerJasvinder A SinghPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
This guideline provides evidence-based recommendations regarding the optimal timing of TJA in patients who have symptomatic and radiographic moderate-to-severe osteoarthritis or advanced symptomatic osteonecrosis with secondary arthritis for whom nonoperative therapy was ineffective to improve patient-important outcomes, including pain, function, infection, hospitalization, and death at 1 year. We acknowledge that the evidence is of low quality primarily due to indirectness and hope future research will allow for further refinement of the recommendations.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- ejection fraction
- newly diagnosed
- quality improvement
- chronic pain
- clinical practice
- chronic kidney disease
- knee osteoarthritis
- prognostic factors
- peritoneal dialysis
- pain management
- patients undergoing
- case report
- disease activity
- metabolic syndrome
- spinal cord injury
- cell therapy
- patient reported outcomes
- stem cells
- juvenile idiopathic arthritis
- skeletal muscle
- systemic lupus erythematosus
- total hip arthroplasty
- glycemic control